HEMOGENYX PHARMACEUTICALS PLC

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. HEMOGENYX PHARMACEUTICALS PLC 2017-10-04 → present
2. SILVER FALCON PLC 2014-11-25 → 2017-10-04
3. SILVER FALCON LIMITED 2013-02-13 → 2014-11-25

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

PKF Littlejohn LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The Directors are of the opinion that the Company has adequate working capital to execute its operations for the present time and is confident in its ability to access additional financing over the next 12 months. The Directors, therefore, have made an informed judgement, at the time of approving these financial statements, that there is a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future, however this relies upon the Company raising additional capital. The Directors have continued to adopt the going concern basis of accounting in preparing the annual financial statements. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's or parent company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.”

Group structure

1. HEMOGENYX PHARMACEUTICALS PLC · parent
   1. Hemogenyx UK Limited 100% · UK · Holding Company
   2. Hemogenyx Pharmaceuticals LLC 100% · USA · Biomedical sciences
   3. Immugenyx LLC 87.3% · USA · Biomedical sciences

Significant events

• “The defining event of the year was the first-in-human administration of HG-CT-1, our proprietary chimeric antigen receptor T cell ("CAR-T") therapy for adult patients with relapsed or refractory acute myeloid leukaemia ("R/R AML"), on 24 February 2025.”
• “In October 2025, the independent Data Safety Monitoring Board ("DSMB") overseeing the trial reviewed the safety data from all three patients treated at the lowest dose level and recommended that the study proceed with escalation to the second dose level. The DSMB simultaneously authorised the initiation of paediatric enrolment at the same starting dose used in adults.”
• “In February 2026, the Company raised £2,475,000 through the placing of 330,000 ordinary shares at £7.50 per share.”
• “In April 2026, the Company raised £3,000,000 through a direct subscription for 374,532 ordinary shares at £8.01 per share.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

11

last 12 months

Capital events

14

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.